Skip to main content
Full access
Letters to the Editor
Published Online: 1 December 2015

Cognition and Plasma Ratio of Clozapine to N-desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia

To the Editor: The report of Tarek K. Rajji et al. (1), published in the June 2015 issue of the Journal, indicated that the plasma ratio of clozapine to N-desmethylclozapine (NDMC) was negatively and specifically associated with working memory function in patients with schizophrenia (N=30). Judging by the relatively low mean total score of 53.7 (range 35–73) on the Positive and Negative Syndrome Scale (PANSS), this appeared to be a group of clozapine-responsive patients (2). We attempted to confirm and extend this finding using available baseline data from a previous randomized controlled trial of patients with clozapine-resistant illness (N=54) (3). In this earlier study, patients were required to be treated for at least 12 weeks (median=84 weeks) with a stable dose of clozapine (≥400 mg/day, unless limited by side effects; median=500 mg/day) prior to testing; as expected, these patients had a much higher mean PANSS total score of 99.5 (range 75–123). Patients were not taking any psychotropic medication except for clozapine. The study included one test of working memory (letter-number sequencing) that was the same and one test that was different (the Brown-Peterson test) from those reported by Rajji et al. We used the same statistical approach, with both tests contributing to a composite assessment of working memory as the dependent variable, and with age, gender, education, total PANSS score, and plasma clozapine/NDMC ratio as simultaneously entered independent variables. The overall model regressing the composite score on all independent variables showed an R2 of 19.6, p=0.056, yet the clozapine/NDMC contribution was weak: β=−0.117, p=0.384. Separate examination of the two contributing tests also failed to confirm an effect of the clozapine/NDMC ratio. In addition, exploratory analyses failed to detect significant associations between the clozapine/NDMC ratio, cognitive domains from the Repeatable Battery for the Assessment of Neuropsychological Status (immediate memory, visuospatial/constructional, language, attention, and delayed memory), or verbal fluency. The failure to confirm the findings of Rajji et al. could be due to insensitivity of cognition in seriously ill patients to subtle variation in occupancy of multiple neuroreceptors by clozapine and NDMC. However, the addition of risperidone to clozapine in our study was associated with deterioration in working memory function, suggesting that plasticity in working memory was present at baseline even in these severely ill patients (3). Much larger studies than the two discussed here, in a wide range of patients with clozapine-responsive and with clozapine-resistant forms of illness (2), are needed to draw more definitive conclusions about the cognitive effects of clozapine, NDMC, and the plasma ratio of these two compounds.

Footnote

The CARE study from which data were derived was registered at ClinicalTrials.gov under number NCT00272584.

References

1.
Rajji TK, Mulsant BH, Davies S, et al: Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry 2015; 172:579–585
2.
Farooq S, Agid O, Foussias G, et al: Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull 2013; 39:1169–1172
3.
Honer WG, Thornton AE, Chen EYH, et al: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354:472–482

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1259
PubMed: 26619773

History

Accepted: September 2015
Published online: 1 December 2015
Published in print: December 01, 2015

Authors

Details

Allen E. Thornton, Ph.D.
The authors represent the Clozapine and Risperidone Enhancement (CARE) Study Group and are from the Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada; and the Departments of Psychiatry and of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, B.C., Canada.
Ric M. Procyshyn, Ph.D.
The authors represent the Clozapine and Risperidone Enhancement (CARE) Study Group and are from the Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada; and the Departments of Psychiatry and of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, B.C., Canada.
Alasdair M. Barr, Ph.D.
The authors represent the Clozapine and Risperidone Enhancement (CARE) Study Group and are from the Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada; and the Departments of Psychiatry and of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, B.C., Canada.
G. William MacEwan, M.D.
The authors represent the Clozapine and Risperidone Enhancement (CARE) Study Group and are from the Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada; and the Departments of Psychiatry and of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, B.C., Canada.
William G. Honer, M.D.
The authors represent the Clozapine and Risperidone Enhancement (CARE) Study Group and are from the Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada; and the Departments of Psychiatry and of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, B.C., Canada.

Competing Interests

Dr. Procyshyn has received speaking and advisory board fees from AstraZeneca, Bristol-Myers Squibb, Janssen, Otsuka, Pfizer, and Sunovion. Dr. Barr has received consulting fees from or served on advisory boards for Bristol-Myers Squibb, Eli Lilly, and Roche. Dr. MacEwan has received research support, speaking, or consulting fees from or served on advisory boards for Apotex, AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Pfizer, and Sunovion. Dr. Honer has received consulting fees from or served on advisory boards for In Silico, Eli Lilly, Lundbeck, Otsuka, and Roche. Dr. Thornton reports no financial relationships with commercial interests.

Funding Information

Stanley Medical Research Institute10.13039/100007123:
The study was supported by the Stanley Medical Research Institute. Dr. Honer was supported by the Jack Bell Chair in Schizophrenia.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share